5 terminated, 1 withdrawn. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 5, Withdrawn 1 |
Follow vilaprisan: new trials by email Literature Review of vilaprisan trials Research Report on vilaprisan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Vilaprisan (BAY1002670), Placebo - Uterine Fibroids | Phase 3 | Withdrawn | Bayer | 2018-10-27 | 2020-01-18 | |
| A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding Vilaprisan (BAY1002670) - Uterine Fibroids and Heavy Menstrual Bleeding | Phase 3 | Terminated | Bayer | 153 | 2018-03-30 | 2022-07-08 |
| Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) Vilaprisan (BAY1002670), Placebo - Uterine Fibroids | Phase 3 | Terminated | Bayer | 103 | 2018-01-24 | 2022-06-30 |
| Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) Vilaprisan (BAY1002670), Placebo - Uterine Fibroids | Phase 3 | Terminated | Bayer | 93 | 2018-01-17 | 2023-05-03 |
| A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Vilaprisan (BAY1002670) - Uterine Fibroids | Phase 3 | Terminated | Bayer | 766 | 2017-07-31 | 2024-10-18 |
| Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Vilaprisan (BAY1002670), Standard of care - Uterine Fibroids | Phase 3 | Terminated | Bayer | 1272 | 2017-06-30 | 2025-07-28 |
Leiomyoma (6) · Menorrhagia (3)
Bayer (6)
Czechia (4) · Japan (4) · United States (3) · Bulgaria (2) · China (2) · Finland (2) · Norway (2) · Poland (2) · Russia (2) · South Africa (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Denmark (1)
2016 (3), 2017 (1)